Table 2.
Kynurenines, TOXO status, and startle variables by diagnostic group.
| Control | Schizophrenia | Chi Sq | p-Valuea | |
|---|---|---|---|---|
| Toxoplasma gondii Status, n | 30 | 47 | ||
| Positive, n (%) | 6 (20.0) | 12 (26.67) | 0.31 | 0.576 |
| Negative, n (%) | 24 (80.0) | 35 (77.78) | ||
| F-value | ||||
| Toxoplasma gondii | 30 | 47 | ||
| Serointensityb, n, Mean (SD) | ||||
| Positive, IU/mL | 68.93 (22.79) | 205.2 (197.1) | 3.41 | 0.086 |
| Negative, IU/mL | 6.79 (5.49) | 5.62 (2.28) | 2.33 | 0.132 |
| Kynureninesc, n, Mean (SD) | 29 | 45 | ||
| Tryptophan, uM | 61.63 (19.26) | 54.66 (11.78) | 5.40 | 0.023 |
| Kynurenine, uM | 2.72 (0.84) | 2.71 (1.03) | 0.00 | 0.970 |
| Kynurenic acid, nM | 47.52 (40.90) | 33.16 (17.02) | 2.79 | 0.099 |
| 3-hydroxyanthranilic | 29.42 (18.34) | 25.85 (13.96) | 0.77 | 0.385 |
| acid, nM | ||||
| Anthranilic acid, nM | 14.85 (18.41) | 14.44 (11.51) | 0.29 | 0.590 |
| Kynurenine:Tryptophan Ratio | 0.05 (0.03) | 0.05 (0.02) | 0.31 | 0.580 |
| 3OHAA:AA Ratiod,e | 2.50 (1.45) | 2.22 (1.20) | 1.00 | 0.320 |
| Startle testing, n, Mean (SD) | 29 | 36 | ||
| Onset Latencyf, ms | 47.87 (11.22) | 48.68 (12.82) | 5.76 | 0.019 |
| Peak Latencyf, ms | 66.55 (11.57) | 70.77 (12.24) | 4.34 | 0.041 |
| Magnitude, μV | 97.48 (74.32) | 211.86 (261.81) | 6.33 | 0.014 |
a
Difference between Control and Schizophrenia subjects.
b
Covariates included: age and diagnosis (CON vs. SCZ).
c
Covariates included: age, sex, diagnosis (CON vs. SCZ), Toxo status (seropositive vs. seronegative).
d
Sample size for this metabolite was 73.
e
3-hydroxyanthranilic acid:Anthranilic acid ratio.
f
Covariates included: age and startle magnitude.